Alliances
Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software
ProBioGen AG announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded expectations.
Physician from Karl Landsteiner University of Health Sciences plays a part in global consensus-building process
Secarna’s proprietary antisense oligonucleotide platform LNAplusTM to be combined with MetP Pharma’s nasal drug delivery technology to develop novel treatment options for neurodegenerative diseases
It has been a busy month for San Francisco-based Nektar Therapeutics. It started with a partnership to pair its lead drug candidate with one developed by pharma giant Pfizer. On Wednesday, the company named a Genentech veteran to helm its oncology programs.
AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to?
Cadent Therapeutics secured $40 million to advance its lead program, CAD-1883.The company also struck a deal with Novartis to develop NMDA modulators.
Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.
Oxurion NV announced today that it entered into a strategic research collaboration with Beta Therapeutics Pty Ltd
Crescendo Biologics Ltd today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.
PRESS RELEASES